Sarepta Therapeutics, Inc. (NASDAQ:SRPT) marched up 142.4% compared to a 52-week low price of $59.51. The shares were last seen trading -4.91% lower, taking the closing price at $144.24 on 2/28/2019. At recent session, the prices were hovering between $145.25 and $155.225. This company shares are 35.64% off its target price of $195.64 and the current market capitalization stands at $9.92B. The recent change has given its price a 17.18% lead over SMA 50 and -18.28% deficit over its 52-week high. The stock witnessed 24.55% gains, 14.38% gains and 7.29% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SRPT’s volatility during a week at 4.68% and during a month it has been found around 4.98%.Sarepta Therapeutics, Inc. (SRPT) Top Holders
Institutional investors currently hold around $10.28 billion or 98.8% in SRPT stock. Look at its top three institutional owners. Fmr Llc owns $1.6 billion in Sarepta Therapeutics, Inc., which represents roughly 16.15% of the company’s market cap and approximately 15.6% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 5,865,323 shares of the stock are valued at $889.65 million. The third largest holder is Blackrock Inc., which currently holds $734.93 million worth of this stock and that ownership represents nearly 7.41% of its market capitalization.Sarepta Therapeutics, Inc. 13F Filings
At the end of December reporting period, 175 institutional holders increased their position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by some 11,080,123 shares, 175 decreased positions by 4,266,638 and 43 held positions by 52,394,828. That puts total institutional holdings at 67,741,589 shares, according to SEC filings. The stock grabbed 51 new institutional investments totaling 1,181,559 shares while 59 institutional investors sold out their entire positions totaling 635,430 shares.Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Trades
Multiple company employees have indulged in significant insider trading. Sarepta Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that EVP, CFO & CBO Mahatme Sandesh has sold 65,000 shares of Sarepta Therapeutics, Inc. (SRPT) in trading session dated Feb. 07, 2019. These shares are worth $9,425,000 and were traded at $145 each. The SEC filing shows that Howton David T performed a sale of 30,000 shares. The SVP, General Counsel disposed these shares by way of transaction on Feb. 01, 2019. The company’s shares were given away at $140 per share worth to an income of some $4,200,000 on account of Howton David T.
SVP, Chief Commercial Officer, Cumbo Alexander, sold 15,000 common shares of Sarepta Therapeutics, Inc. (SRPT) in the open market. In a transaction dated Feb. 01, 2019, the shares were put up for sale at an average price of $140, raking in a sum of $2,100,000. After this sale, 15,266 common shares of SRPT are directly owned by the insider, with total stake valued at $2,201,968.
In the transaction dated Jan. 31, 2019, the great number of shares disposed came courtesy the EVP, CFO & CBO; Mahatme Sandesh disposed a total of 65,000 shares at an average price of $130.23, amounting to approximately $8,464,950. The insider now directly owns 20,661 shares worth $2,980,143.Sarepta Therapeutics, Inc. (SRPT) Analyst Guide
Several analysts have released their opinion on Sarepta Therapeutics, Inc. (NASDAQ:SRPT), with 8 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 13 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.68 average brokerage recommendation.